256 |
Current Status of TAVR in Japan |
Kentaro Hayashida |
Aug. 08. 19 |
255 |
Percutaneous Closure of PFO Is Still Underutilized! |
Jae Young Choi |
Aug. 08. 19 |
254 |
Mechanical Valve: It Is Still Strong. |
Byung Chul Chang |
Aug. 08. 19 |
253 |
Tissue Valve for All AS Patients: Safe and Well-proven Option |
Suk Jung Choo |
Aug. 08. 19 |
252 |
It Is Early to Tell TAVR in All Patients with Aortic Stenosis. |
Jian (James) Ye |
Aug. 08. 19 |
251 |
TAVR Will Be a Standard Treatment for All Patients with Aortic Stenosis |
Duk-Woo Park |
Aug. 08. 19 |
250 |
Mitral Valve-in-Valve and Valve-in-Ring: Outcomes and Procedural Considerations |
Eberhard Grube |
Aug. 08. 19 |
249 |
Quality of Life Outcomes of Transcatheter Mitral Valve Repair: Insights from the COAPT |
David Joel Cohen |
Aug. 08. 19 |
248 |
Percutaneous Mitral Valve Repair: Current Status and Future Perspectives |
Eberhard Grube |
Aug. 08. 19 |
247 |
Antithrombotics After PFO Device Closure: What and How Long? |
Woong Chol Kang |
Aug. 08. 19 |